Diametric Capital’s Bionano Genomics BNGO Stock Holding History

Diametric Capital’s Portfolio BNGO Stock Details BNGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-23	Closed	-$19K	–	263
2022 Q2	$19K	Buy	+23	New	+$23.7K	0.01%	259

Other funds holding BNGO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $149B AUM 24.71% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Diametric Capital's BNGO Position: Q3 2022 in Review

Diametric Capital sold out of Bionano Genomics (BNGO) in Q3 2022, closing a stake of 23 shares — an estimated $19K sold.

Diametric Capital first reported a position in BNGO in Q2 2022 and held it in 1 quarter. The position peaked at $19K in Q2 2022. 140 funds tracked by Wall St. Rank hold BNGO as of Q3 2022.

Diametric Capital reported no remaining Bionano Genomics position as of Q3 2022 after selling out during the quarter.
Diametric Capital sold 23 Bionano Genomics shares in Q3 2022, an estimated $19K.
Diametric Capital first reported a position in Bionano Genomics in Q2 2022 and held it in 1 quarter.
Diametric Capital's Bionano Genomics position peaked at $19K in Q2 2022.
140 funds tracked by Wall St. Rank held Bionano Genomics as of Q3 2022.

Based on Diametric Capital's 13F filing for Q3 2022, filed 14 Nov 2022.